Navigation Links
IDM Pharma Announces Presentations at 44th American Society of Clinical Oncology Annual Meeting
Date:5/16/2008

IRVINE, Calif., May 16 /PRNewswire-FirstCall/ -- IDM Pharma, Inc. (Nasdaq: IDMI) today announced that clinical data presentations evaluating the Company's lead product candidates will be made at the upcoming 44th American Society of Clinical Oncology (ASCO) annual meeting. Data presented at the meeting will support improved survival for patients with metastatic osteosarcoma treated with L-MTP-PE, as well as patients with non-small lung cancer treated with IDM-2101.

Presentation highlights are as follows:

L-MTP-PE

"Addition of Muramyl Tripeptide to Chemotherapy for Patients with Newly

Diagnosed Metastatic Osteosarcoma: a Report from the Children's Oncology

Group"

Presenter: Alexander J Chou, MD, Department of Pediatrics, Memorial

Sloan-Kettering Cancer Center

Date/Time: Poster presentation, Sunday, June 1, 2008, 2 - 6 p.m., S Hall

A1; poster discussion period, 4:45 - 6 p.m., S504

Abstract Number: 10018

Poster Number: 52B

IDM-2101

"Induction of immune responses and clinical activity in a Phase 2 trial of

IDM-2101, a 10-epitope CTL vaccine, in metastatic NSCLC patients"

Presenter: Minal Barve, MD, practice director, Mary Crowley Cancer

Research Center

Date/Time: Sunday, June 1, 2008, 2 - 6 p.m., S Hall A1

Abstract Number: 8057

Poster Number: 43D

The 2008 ASCO annual meeting abstracts are currently available at http://www.asco.org.

About IDM Pharma

IDM Pharma is focused on the development of innovative cancer products that either destroy cancer cells by activating the immune system or prevent tumor recurrence by triggering a specific adaptive immune response. IDM Pharma is dedicated to maximizing the full therapeutic and commercial potential of each of its innovative products to address the needs of patients and the physicians who treat these patients.

For more information about the company and its products, visit http://www.idm-pharma.com.

Forward-Looking Statements

The presentations described in this press release will include forward- looking statements that reflect management's current views of future events regarding the development and characteristics of the Company's drug candidates L-MTP-PE and IDM-2101, including the Company's plans to address the remaining questions with respect to the Marketing Authorization Application (MAA) for L- MTP-PE during the clock-stop granted by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency, and the expected timing of a final opinion from the CHMP and of a final regulatory decision regarding the MAA in the European Union, as well as the Company's plans to collect, analyze and submit additional Phase 3 data in an amended New Drug Application (NDA) for L-MTP-PE, including the expected timing for such amended NDA, and to respond to other matters raised by the Food and Drug Administration (FDA), the potential for IDM-2101 as a treatment for NSCLC and plans to evaluate strategic alternatives. Actual results may differ materially from the forward- looking statements due to a number of important factors, including, but not limited to, whether the Company will be able to respond to the remaining issues with regard to the MAA, including verification of data quality and chemistry, manufacturing and controls (CMC) items, to the satisfaction of the CHMP, whether the CHMP will ask the Company for further information at or following the June 2008 meeting to address remaining issues with regard to the MAA, which would delay the timing of a final opinion from the CHMP, whether the final opinion of the CHMP will be consistent with the non-binding opinion of the CHMP, whether the European Commission will follow the final opinion of the CHMP once issued, whether the timing for the final opinion of the CHMP and the regulatory decision in Europe will occur as expected by the Company, the possibility that additional data from the Phase 3 clinical trial of L-MTP-PE and other information in any amendment to the NDA for L-MTP-PE submitted by the Company may not provide adequate support for regulatory approval of L-MTP- PE in the United States within the timeframe expected by the Company, if at all, whether the Company will be able to manufacture and commercialize L-MTP- PE even if it is approved by regulatory authorities, whether the Company will be able to complete any potential strategic transaction on terms acceptable to the Company's stockholders, and whether the cash resources of the Company will be sufficient to fund operations as planned. These and other risks affecting the Company and its drug development programs, intellectual property rights, personnel and business are more fully discussed in the Company's Quarterly Report on Form 10-Q filed with the SEC for the quarter ended March 31, 2008 and other periodic reports filed with the SEC. The Company expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.


'/>"/>
SOURCE IDM Pharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Jazz Pharmaceuticals to Present at Investor Conferences
2. Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008
3. Carlos A. Parra Joins Alexza Pharmaceuticals as Vice President, Quality
4. Pharmasset Reports Financial Results for Quarter Ended March 31, 2008
5. Wyeths Pristiq, a New Treatment for Major Depressive Disorder in Adults, Now Available in U.S. Pharmacies
6. Tianyin Pharmaceutical Co., Inc. Announces Third Quarter 2008 Financial Results
7. 11 Pharmaceutical Titans Headline Chemistry Outsourcing Conference Program in September in New Jersey
8. AMDL Subsidiary Donates Pharmaceuticals in China Earthquake Relief Effort
9. Alseres Pharmaceuticals, Inc. Reports First Quarter 2008 Operational and Financial Results
10. Pharmacyclics Files Schedule 14D-9 Statement with Securities and Exchange Commission
11. Medsn to Become Indegene Pharmaceutical Solutions, Inc.: Change Signifies the Success of Its Innovative Global Services Model
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... 28, 2017 , ... Accreditation Commission for Health Care (ACHC) ... America (HCAOA). This agreement allows HCAOA members to receive special pricing on ACHC’s ... Accreditation University (AU) educational resources that help prepare HCAOA members for ACHC Accreditation. ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... Getting enough sleep affects much more than ... (NSF), going just 19 hours without sleep can compromise motor reaction time, which can increase ... and Amica Insurance is sharing the following tips from the NSF to help you sleep ...
(Date:4/28/2017)... ... April 28, 2017 , ... Datta Endoscopic Back Surgery ... the revolutionary endoscopic practice under Dr. Datta. Patel is a Board Certified Anesthesiologist, ... patented, revolutionary eDiscSculpt Technique created and used by Datta Endoscopic is unlike traditional ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... People are ... older people. “Wearing a hearing aid doesn’t have the stigma it had when great-grandpa ... Hearing Associates of Greater Boston, in a NALA North American Speaker Series ...
(Date:4/28/2017)... ... April 28, 2017 , ... Intellitec Solutions ... Grove Foundation implement a Microsoft Dynamics GP solution that integrates to their PointClickCare ... that specializes in long-term care, Brooke Grove now has the capability to achieve ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... Calif. , April 19, 2017  IRIDEX Corporation ... will release financial results for the first quarter 2017 ... 2017.  The Company,s management team will host a corresponding ... p.m. ET. Investors interested in listening to ... 707-0665 for domestic callers or (703) 326-3030 for international ...
(Date:4/19/2017)... NEW YORK , April 19, 2017 /PRNewswire/ ... This report on the prostate cancer ... of the global market. Increasing prevalence of prostate ... as innovation in the development of new drugs ... hormone-refractory prostate cancer drug due to lesser side ...
(Date:4/19/2017)... India , April 19, 2017 ... and Application, Forecast to 2022 report has covered and analysed ... statistics and information on market size, shares and growth factors. ... major drivers, challenges and opportunities in the global market. ... Browse 152 Tables and Figures, ...
Breaking Medicine Technology: